Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - oxycodone hydrochloride, quantity: 40 mg; naloxone hydrochloride dihydrate, quantity: 21.8 mg (equivalent: naloxone hydrochloride?, qty 20 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; iron oxide yellow; ethylcellulose; magnesium stearate; polyvinyl alcohol; povidone; titanium dioxide; purified talc; macrogol 3350; stearyl alcohol - targin modified release tablet is indicated for the management of severe pain where:,- other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and,- the pain is opioid-responsive; and,- requires daily, continuous, long term treatment.,targin modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances.,targin modified release tablet is not indicated as an as-needed (prn) analgesia,the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.,targin is indicated as a second line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome after failure of dopaminergic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - naloxone hydrochloride dihydrate, quantity: 10.9 mg (equivalent: naloxone hydrochloride?, qty 10 mg); oxycodone hydrochloride, quantity: 20 mg - tablet, modified release - excipient ingredients: magnesium stearate; povidone; macrogol 3350; stearyl alcohol; titanium dioxide; lactose monohydrate; purified talc; polyvinyl alcohol; iron oxide red; ethylcellulose - targin modified release tablet is indicated for the management of severe pain where:,- other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and,- the pain is opioid-responsive; and,- requires daily, continuous, long term treatment.,targin modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances.,targin modified release tablet is not indicated as an as-needed (prn) analgesia,the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.,targin is indicated as a second line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome after failure of dopaminergic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - oxycodone hydrochloride, quantity: 10 mg; naloxone hydrochloride dihydrate, quantity: 5.45 mg (equivalent: naloxone hydrochloride?, qty 5 mg) - tablet, modified release - excipient ingredients: titanium dioxide; lactose monohydrate; stearyl alcohol; macrogol 3350; ethylcellulose; polyvinyl alcohol; purified talc; magnesium stearate; povidone - targin modified release tablet is indicated for the management of severe pain where:,- other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and,- the pain is opioid-responsive; and,- requires daily, continuous, long term treatment.,targin modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances.,targin modified release tablet is not indicated as an as-needed (prn) analgesia,the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.,targin is indicated as a second line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome after failure of dopaminergic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - oxycodone hydrochloride, quantity: 5 mg; naloxone hydrochloride dihydrate, quantity: 2.73 mg (equivalent: naloxone hydrochloride?, qty 2.5 mg) - tablet, modified release - excipient ingredients: ethylcellulose; macrogol 3350; brilliant blue fcf aluminium lake; stearyl alcohol; polyvinyl alcohol; titanium dioxide; magnesium stearate; lactose monohydrate; purified talc; hyprolose - targin modified release tablet is indicated for the management of severe pain where:,- other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and,- the pain is opioid-responsive; and,- requires daily, continuous, long term treatment.,targin modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances.,targin modified release tablet is not indicated as an as-needed (prn) analgesia,the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.,targin is indicated as a second line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome after failure of dopaminergic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin acetate, quantity: 0.2 mg (equivalent: desmopressin, qty 178 microgram) - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; povidone; potato starch - minirin tablets are indicated for the treatment of: cranial diabetes insipidus; primary nocturnal enuresis, in patients from 6 years of age with normal ability to concentrate urine, who are refractory to an enuresis alarm, or in whom an enuresis alarm is contraindicated or inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril arginine, quantity: 10 mg; amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg) - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica - perindopril arginine and amlodipine combination tablet is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg); perindopril arginine, quantity: 5 mg - tablet - excipient ingredients: colloidal anhydrous silica; croscarmellose sodium; microcrystalline cellulose; magnesium stearate - perindopril arginine and amlodipine combination tablet is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril arginine, quantity: 10 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose - perindopril arginine and amlodipine combination tablet is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); perindopril arginine, quantity: 5 mg - tablet - excipient ingredients: colloidal anhydrous silica; croscarmellose sodium; microcrystalline cellulose; magnesium stearate - perindopril arginine and amlodipine combination tablet is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - artemether, quantity: 20 mg; lumefantrine, quantity: 120 mg - tablet, dispersible - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; crospovidone; saccharin sodium; hypromellose; magnesium stearate; polysorbate 80; colloidal anhydrous silica; flavour - riamet tablet is indicated for the treatment of acute, uncomplicated malaria due to plasmodium falciparum in adults, children and infants of 5kg and above. riamet dispersible tablet is indicated for the treatment of acute, uncomplicated malaria due to plasmodium falciparum in children and infants weighing between 5kg and less than 35kg.